Navigation Links
Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
Date:4/1/2013

LA JOLLA, Calif., April 1, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has appointed William H. Rastetter , Ph.D. to its Board of Directors effective immediately. 

"We are extremely pleased to have Bill join our Board," said John Maraganore , Ph.D., Chairman of the Board of Directors of Regulus and CEO of Alnylam Pharmaceuticals, Inc. "Bill is an industry legend who has invented, developed and commercialized highly transformative therapies. He will be a valuable resource as we continue to grow the company and develop first-in-class medicines targeting microRNAs."

"Regulus' approach to treating complex, multi-factorial diseases by targeting microRNAs is very exciting," said Dr. Rastetter.  "I believe that Regulus' therapeutic platform has significant scientific and commercial potential and I look forward to collaborating with the Regulus team and Board of Directors to realize the power of microRNA therapeutics."

Dr. Rastetter served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003, and as Chairman from May 1996 to November 2003.  Upon the merger of IDEC Pharmaceuticals and Biogen in November 2003, Dr. Rastetter served as Executive Chairman of Biogen Idec until the end of 2005. From 2006 to 2013, Dr. Rastetter served as a partner in the venture capital firm, Venrock.  Dr. Rastetter currently serves as the Chairman of the Board of Directors of Fate Therapeutics, Inc., Illumina, Inc., Neurocrine Biosciences and Receptos, Inc.  He is the author of numerous scientific papers and patent applications in the fields of organic and bioorganic chemistry, protein and enzyme engineering, and biotechnology. Dr. Rastetter holds a S.B. in Chemistry from the Massachusetts Institute of Technology and received his M.A. and Ph.D. in Chemistry from Harvard University.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals and Isis Pharmaceuticals. Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
2. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
3. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
4. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
5. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
6. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
7. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
8. Regulus Appoints Mark G. Foletta to its Board of Directors
9. Regulus to Present at Two Upcoming Investor Conferences
10. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
11. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... that offers insurance and financial preparation services, is providing an update on a ... organization. , Rock City Rescue is a locally recognized nonprofit that provides shelter ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of Eating ... excellence for the field of eating disorders, announces the opening of early registration ... Orlando, Florida at the Omni Resort at ChampionsGate. , The annual ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
Breaking Medicine News(10 mins):